# Nautilus Biotechnology (NAUT) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/NAUT
## Company Profile
- Ticker: NAUT
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 0.8997 USD
- Market cap: 340571331.40000004 USD
- Last updated: 2026-08-12
## Business Overview
### Single-Molecule Proteomics Platform
Nautilus Biotechnology is a development-stage life sciences company building a single-molecule proteomics platform intended to make comprehensive protein analysis more accessible. The platform is designed to quantify proteins and their proteoforms at scale, supporting research in disease biology, diagnostics, and drug development.
### Voyager Instrument Platform
The Nautilus Voyager Platform is the company’s planned commercial instrument system. It is being designed to bring highly multiplexed single-molecule protein analysis into research and drug-development workflows.
### Assay-Led Early Access
Before broad instrument availability, Nautilus is engaging customers through its Iterative Mapping Early Access service. The Tau Proteoforms Assay is the first available application, with AKT1 selected as the first oncology-focused proteoform assay.
### Instrument and Consumables Model
Nautilus plans to progress from early-access services to a commercial model combining instruments, consumable kits, and targeted proteoform assays. This approach is intended to create recurring demand as the installed instrument base and application menu expand.
## Why The Stock Is Moving

As of Aug 12, 2026, NAUT closed up 1.00% at $0.8997. No new same-company headline was identified in the current news window.

## Future Catalysts

- The AKT1 Proteoforms Assay is expected to enter Iterative Mapping Early Access by the end of 2026.
- Voyager Platform preorders are expected to open in early 2027, with initial instrument shipments planned for mid-2027.
- Consumable kits for the Tau, AKT1, and a second oncology proteoform assay are expected to become generally available in mid-2027, followed by a third oncology assay and additional kits by year-end 2027.

## Recent News
- 2026-07-28 12:00 EST — [Nautilus Biotechnology Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-reports-second-quarter-2026-financial-results-6bb2d24b) — Source: Nautilus Biotechnology
- 2026-07-08 12:00 EST — [Nautilus Biotechnology to Announce Second Quarter 2026  Financial Results on July 28, 2026](https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-to-announce-second-quarter-2026-financial-results-on-july-ffc9b6aa) — Source: Nautilus Biotechnology
- 2026-04-28 12:00 EST — [Nautilus Biotechnology Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-reports-first-quarter-2026-financial-results-be1ada7a) — Source: Nautilus Biotechnology
- 2026-04-09 12:00 EST — [Nautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026](https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-to-announce-first-quarter-2026-financial-results-on-april-a00320ac) — Source: Nautilus Biotechnology
- 2026-03-24 12:00 EST — [Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference](https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-to-participate-in-the-investor-summit-group-virtual-confe-1d3fd49b) — Source: Nautilus Biotechnology